Community Medical Services: Company Profile

Background

Overview

Community Medical Services (CMS) is a leading provider of outpatient medication-assisted treatment (MAT) for individuals with opioid use disorder (OUD). Established in 1983 and headquartered in Scottsdale, Arizona, CMS operates over 70 clinics across 13 states, offering evidence-based treatments, counseling, and peer support services to more than 39,000 patients annually.

Mission and Vision

CMS is dedicated to delivering compassionate, judgment-free care to those affected by substance use disorders. Their mission is to provide accessible, high-quality treatment that empowers individuals to achieve lasting recovery and improve their quality of life.

Industry Significance

As a pioneer in the MAT field, CMS has been instrumental in expanding access to OUD treatment, particularly in underserved areas. Their innovative approaches, such as the nation's first 24-hour Opioid Treatment on Demand (OTOD) center, have set new standards in the industry.

Key Strategic Focus

Core Objectives

Expansion of Services: CMS aims to increase the availability of MAT services by opening new clinics and enhancing existing facilities.

Community Engagement: The organization focuses on building partnerships with local communities to reduce stigma and promote education about OUD treatment.

Comprehensive Care: CMS emphasizes a holistic approach, integrating counseling, peer support, and harm reduction strategies into their treatment programs.

Areas of Specialization

Medication-Assisted Treatment: Utilizing FDA-approved medications like methadone, buprenorphine (Suboxone), and naltrexone to manage withdrawal symptoms and cravings.

Counseling and Peer Support: Providing individual and group counseling sessions, as well as peer support groups, to address the psychological aspects of recovery.

Harm Reduction Initiatives: Implementing programs such as naloxone distribution and harm reduction vending machines to prevent overdose deaths.

Key Technologies Utilized

Telemedicine: Expanding access to care through virtual consultations, especially in remote areas.

Mobile Applications: Developing tools like the Recovery Connect App to support patients in their recovery journey.

Primary Markets Targeted

CMS primarily serves individuals with opioid use disorder, focusing on both urban and rural communities across the United States.

Financials and Funding

Funding History

CMS has experienced significant growth, expanding from a single clinic to over 70 locations. In 2018, the company was acquired by Clearview Capital, a private equity firm, which provided the necessary capital to fuel this expansion.

Recent Funding Rounds

Specific details about recent funding rounds are not publicly disclosed.

Notable Investors

Clearview Capital: Acquired CMS in 2018, supporting its growth and expansion initiatives.

Utilization of Capital

The capital has been utilized for:

Clinic Expansion: Opening new treatment centers in underserved regions.

Technology Integration: Implementing telemedicine services and developing mobile applications.

Community Outreach: Funding programs aimed at reducing stigma and educating the public about OUD treatment.

Pipeline Development

Key Pipeline Candidates

CMS focuses on expanding its network of clinics and enhancing service offerings rather than developing pharmaceutical products.

Stages of Development

Clinic Expansion: Ongoing efforts to establish new facilities in various states.

Service Enhancement: Integrating additional services such as mental health counseling and housing support.

Target Conditions

Opioid Use Disorder (OUD)

Anticipated Milestones

Short-Term: Opening new clinics in identified high-need areas.

Medium-Term: Achieving CARF (Commission on Accreditation of Rehabilitation Facilities) accreditation for all clinics.

Long-Term: Establishing CMS as a national leader in OUD treatment with a comprehensive network of services.

Technological Platform and Innovation

Proprietary Technologies

Recovery Connect App: A mobile application designed to support patients in their recovery journey by providing resources, tracking progress, and facilitating communication with counselors.

Significant Scientific Methods

Evidence-Based Practices: Implementing treatment protocols grounded in scientific research to ensure the effectiveness of MAT programs.

Data Analytics: Utilizing data to monitor patient outcomes and continuously improve treatment strategies.

Leadership Team

Nick Stavros – Chief Executive Officer

Nick Stavros has been with CMS for over a decade, serving as CEO. A U.S. Army veteran and MBA graduate from UCLA, he has been instrumental in CMS's growth and strategic direction.

Laura Contreras – Chief Financial Officer

Joining CMS in February 2024, Laura brings over 30 years of financial management experience, including roles in healthcare-related industries. She holds an undergraduate degree in Accounting from Colorado State University Denver.

Christopher Flowers – Chief Operating Officer

Appointed in January 2024, Christopher has over 15 years of operational leadership experience. He earned his MBA from Texas Tech University and focuses on developing successful management teams and improving processes.

Dr. Robert Sherrick, MD, FASAM – Chief Science Officer

Dr. Sherrick transitioned to CSO in 2023 after serving as Chief Medical Officer for six years. He is board-certified in Addiction Medicine and has been providing MAT for OUD since 2003. He holds an MD from George Washington University Medical Center.

Stacie Baird – Chief People Officer

Since 2022, Stacie has led the Employee Experience Team, focusing on building trust and leading change across CMS's distributed workforce. She holds a BS in Chemistry with a focus on Pharmacology from Butler University.

Michael Hailye, CISSP – Chief Technology Officer

Appointed in March 2022, Michael leads the IT team and external vendor relationships. He holds a BS in Aeronautical Engineering from Rensselaer Polytechnic Institute and a Master of Engineering in Aerospace Engineering from the University of Michigan.

Jennifer Mason – Executive Vice President of Operations

With over 20 years in the MAT/MOUD space, Jennifer joined CMS in 2015 and was promoted to her current role in 2022. She holds a degree in Business with an emphasis on Organizational Leadership from Southern New Hampshire University.

Hillary Tamar, M.D. – Medical Director, Eastern Territory

Dr. Tamar oversees medical care in Ohio, Texas, Indiana, Michigan, Wisconsin, and Minnesota. She completed a fellowship in Addiction Medicine at Swedish Medical Center and is board-certified in both Family Medicine and Addiction Medicine.

Competitor Profile

Market Insights and Dynamics

The MAT industry is experiencing significant growth due to the opioid crisis, with increasing demand for treatment services. Key competitors include BayMark Health Services, which specializes in MAT, and other healthcare providers offering similar services.

Competitor Analysis

BayMark Health Services: A direct competitor specializing in MAT, offering a range of services across multiple states.

HCA Healthcare: A large healthcare provider with a broad range of services, including addiction treatment programs.

Tenet Healthcare: Operates hospitals and outpatient centers, some of which offer addiction treatment services.

Strategic Collaborations and Partnerships

CMS collaborates with hospitals, correctional health programs, recovery housing, and public health entities to expand access to evidence-based OUD care.

Operational Insights

CMS's focus on low-barrier access to care, evidenced by no waitlists and walk-ins always welcome, differentiates it from competitors.

Strategic Opportunities and Future Directions

CMS plans to continue expanding its clinic network, integrate additional services such as mental health counseling, and enhance community outreach to further reduce stigma associated with OUD treatment.